ReviewClinical and experimental immunology2013
Protecting against plague: towards a next-generation vaccine.
Review in Clinical and experimental immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 54 citations in OpenAlex.
- Immunogenicity and safety of subunit plague vaccine: A randomized phase 2a clinical trial.Human vaccines & immunotherapeutics · 2016Trial
- An adenoviral-vectored vaccine protects mice against aerosol challenge with Yersinia pestis.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Nanolipoprotein particle (NLP) vaccine confers protection againstFrontiers in immunology · 2025Article
- Functional assays to screen and select monoclonal antibodies that targetHuman vaccines & immunotherapeutics · 2023Article
- Polyclonal Antibodies Derived from Transchromosomic Bovines Vaccinated with the Recombinant F1-V Vaccine Increase Bacterial Opsonization In Vitro and Protect Mice from Pneumonic Plague.Antibodies (Basel, Switzerland) · 2023Article
- A single-dose F1-based mRNA-LNP vaccine provides protection against the lethal plague bacterium.Science advances · 2023Article
- Article
- Optimised Heterologous Expression and Functional Analysis of theInternational journal of molecular sciences · 2021Article
- Plague vaccines: new developments in an ongoing search.Applied microbiology and biotechnology · 2021Review
- Protection Elicited by Attenuated LiveVaccines · 2021Article
- Short- and long-term humoral immune response against Yersinia pestis in plague patients, Madagascar.BMC infectious diseases · 2020Article
- Development of a multiple-antigen protein fusion vaccine candidate that confers protection against Bacillus anthracis and Yersinia pestis.PLoS neglected tropical diseases · 2019Article
- Polymorphism in theFrontiers in immunology · 2019Article
- Plague vaccine: recent progress and prospects.NPJ vaccines · 2019Review
- Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia.Scientific reports · 2018Article
- Targeting of theNPJ vaccines · 2018Article
- Particulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogens.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2017Review
- YopE specific CD8+ T cells provide protection against systemic and mucosal Yersinia pseudotuberculosis infection.PloS one · 2017Article
- Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague.Vaccine · 2016Article
- A Recombinant Trivalent Fusion Protein F1-LcrV-HSP70(II) Augments Humoral and Cellular Immune Responses and Imparts Full Protection against Yersinia pestis.Frontiers in microbiology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The causative organism of plague is the bacterium Yersinia pestis. Advances in understanding the complex pathogenesis of plague infection have led to the identification of the F1- and V-antigens as key components of a next-generation vaccine for plague, which have the potential to be effective against all forms of the disease. Here we review the roles of F1- and V-antigens in the context of the range of virulence mechanisms deployed by Y. pestis, in order to develop a greater understanding of the protective immune responses required to protect against plague.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.